Navigating the Future: 10 Key Elements of AI Project Management in Biopharma

6- Intellectual Property and Competitive Intelligence

The biopharma industry is built on intellectual property, and AI projects generate complex IP considerations. Project managers must navigate patent landscapes, protect proprietary algorithms and datasets, and ensure freedom to operate in crowded therapeutic areas.

This requires close collaboration with legal teams to conduct thorough patent searches, file appropriate protections, and structure partnerships that preserve and leverage competitive advantages. The challenge is particularly acute when working with external data sources, academic collaborators, or technology vendors.

Competitive intelligence also becomes crucial as the AI biopharma landscape evolves rapidly. Project managers must stay informed about competitive AI initiatives, regulatory precedents, and emerging best practices that could impact their projects.

7- Technology Infrastructure and Scalability Planning

Biopharma AI projects often begin as research initiatives but must scale to production systems that can handle real-world clinical workflows. Project managers must plan for this scaling from the project’s inception, ensuring that proof-of-concept work can evolve into robust, validated systems.

This includes establishing cloud infrastructure that meets regulatory requirements, implementing MLOps practices for model deployment and monitoring, and ensuring integration capabilities with existing clinical and commercial systems.

Security requirements are particularly stringent, often requiring on-premises or private cloud deployments with extensive audit trails and access controls. Project managers must balance these security needs with the collaborative requirements of AI development teams.

8- Change Management and User Adoption

Even the most sophisticated AI system fails if clinicians and other end users don’t adopt it effectively. Project managers must develop comprehensive change management strategies that address the cultural, workflow, and training challenges of AI implementation in clinical settings.

This requires a deep understanding of clinical workflows, stakeholder concerns about AI replacing human judgment, and the practical challenges of integrating AI recommendations into existing decision-making processes. Training programs must be developed not just for technical users but for all stakeholders who will interact with AI-driven insights.

Pilot programs and phased rollouts become essential tools for managing change, allowing teams to refine both the technology and the implementation approach based on real-world feedback.

9- Performance Monitoring and Model Lifecycle Management

Unlike traditional software, AI models can degrade over time as data distributions change or new treatments emerge. Project managers must establish comprehensive monitoring systems that track model performance, detect drift, and trigger retraining or recalibration when necessary.

This requires defining appropriate performance metrics that align with clinical outcomes, establishing monitoring thresholds, and creating procedures for model updates that maintain regulatory compliance. The challenge is particularly complex in biopharma, where model updates may require regulatory approval.

Lifecycle management must also account for the evolution of clinical practice, new therapeutic options, and changing patient populations that might affect model relevance and performance over time.

10- Value Demonstration and ROI Measurement

Biopharma AI projects require significant investments and must demonstrate clear value to justify continued funding and expansion. Project managers must establish metrics and measurement frameworks that capture both quantitative benefits like cost savings or time reductions and qualitative benefits like improved decision-making or patient outcomes.

This often requires developing novel measurement approaches, as traditional ROI calculations may not capture the full value of AI in drug development or clinical care. Value demonstration must be ongoing throughout the project, not just at completion, to maintain stakeholder support and secure additional resources.

The challenge is particularly acute for AI projects with long development timelines, where benefits may not be realized for years. Project managers must identify and communicate interim value milestones that demonstrate progress toward ultimate objectives.

Conclusion

Managing AI projects in biopharma requires a sophisticated understanding of both cutting-edge technology and one of the world’s most regulated industries. Success depends on integrating these ten elements into a coherent project management approach that balances innovation with compliance, speed with safety, and technical excellence with clinical utility.

The future of healthcare depends on our ability to successfully implement AI solutions that improve patient outcomes while meeting the highest standards of safety and efficacy. Project managers who master these key elements will be instrumental in delivering on that promise, thereby transforming both the pharmaceutical industry and patient care.

As the field continues to evolve, these fundamental elements will remain crucial, even as new challenges and opportunities emerge. The investment in building strong AI project management capabilities today will pay dividends in the revolutionary healthcare solutions of tomorrow.

References

1- FDA’s Latest AI Guidance (January 2025): “Considerations for the Use of Artificial Intelligence (AI) To Support Regulatory Decision-Making for Drug and Biological Products” The Role of AI in Regulatory Decision-Making for Drugs & Biologics: the FDA’s Latest Guidance | WCG

2- FDA CDER AI Council (2024): The CDER AI Council, established in 2024 to provide oversight, coordination, and consolidation of CDER activities around AI use Artificial Intelligence for Drug Development | FDA

3- FDA Discussion Papers on AI/ML: “Using Artificial Intelligence and Machine Learning in the Development of Drug and Biological Products,” and “Artificial Intelligence in Drug Manufacturing” FDA Releases Two Discussion Papers to Spur Conversation about Artificial Intelligence and Machine Learning in Drug Development and Manufacturing | FDA

4- McKinsey on Generative AI in Pharma (January 2024): Generative AI could offer the pharma industry a once-in-a-century opportunity—but only if they learn to scale it and address the industry’s unique challenges Generative AI in the pharmaceutical industry: Moving from hype to reality

5- McKinsey on AI Integration (October 2022): By focusing on specific scientific and operational pain points and fully integrating AI into research workflows, pharma companies can deliver greater patient impact Harnessing the AI/ML in Drug and Biological Products Discovery and Development: The Regulatory Perspective – PMC

6- PMC Article on AI Validation: Prioritizing patient safety, AI models must undergo thorough validation and testing to ensure their reliability and accuracy Q&A with FDA: AI in Clinical Trial Design and Research

7- Salesforce Healthcare AI Guidelines: Set clear guidelines on AI development and use, covering data validation, training practices, and compliance standards Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design – PMC

8- Clinical Trial AI Applications: By analyzing data, AI is already uncovering new therapeutic targets, optimizing clinical trial designs, and predicting patient responses with greater accuracy How AI is being used to accelerate clinical trials

9- Nature Article on AI in Clinical Trials: Discusses technology acceleration in clinical research processes

10- PMC Regulatory Perspective Article: Artificial Intelligence (AI) has the disruptive potential to transform patients’ lives via innovations in pharmaceutical sciences, drug development, clinical trials, and manufacturing.

About the author: Kossi Molley, Chemist; LSSBB; PMP